SAB Biotherapeutics (SABS) Income towards Parent Company (2021 - 2026)
SAB Biotherapeutics (SABS) posted Income towards Parent Company of -$46.5 million for Q1 2026, down 219.16% on a QoQ basis from -$14.6 million in Q4 2025, and down 323.92% year-over-year from $20.8 million in Q1 2025.
SAB Biotherapeutics (SABS) Income towards Parent Company (2021 - 2026) Analysis & Trends
SAB Biotherapeutics' Income towards Parent Company history runs 6 years deep, the most recent figure standing at -$46.5 million for Q1 2026.
- Quarterly Income towards Parent Company fell 323.92% year-over-year to -$46.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$84.3 million (down 118.02% YoY) and the FY2025 annual result came in at -$73.6 million, down 71.9% from the prior year.
- Income towards Parent Company was -$46.5 million for Q1 2026 at SAB Biotherapeutics, down from -$14.6 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $985863.0 in Q1 2022 and bottomed at -$46.5 million in Q1 2026.
- A 5-year average of -$11.1 million and a median of -$7.8 million in 2022 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2023 — Income towards Parent Company plunged 845.93% — and 2024, when it surged 56.25%.
- SAB Biotherapeutics' Income towards Parent Company stood at -$7.8 million in 2022, then plunged by 191.21% to -$22.9 million in 2023, then jumped by 56.25% to -$10.0 million in 2024, then tumbled by 45.71% to -$14.6 million in 2025, then plunged by 219.16% to -$46.5 million in 2026.
- Business Quant data shows SABS's Income towards Parent Company at -$46.5 million in Q1 2026, -$14.6 million in Q4 2025, and -$12.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | SAB Biotherapeutics | 185.85 Mn | 185.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.51 Mn |
| Dec 31, 2025 | -14.57 Mn |
| Sep 30, 2025 | -12.75 Mn |
| Jun 30, 2025 | -10.45 Mn |
| Mar 31, 2025 | -10.97 Mn |
| Dec 31, 2024 | -10.00 Mn |
| Sep 30, 2024 | -10.35 Mn |
| Jun 30, 2024 | -7.34 Mn |
| Mar 31, 2024 | -5.03 Mn |
| Dec 31, 2023 | -22.86 Mn |
| Sep 30, 2023 | -5.10 Mn |
| Jun 30, 2023 | -6.88 Mn |
| Mar 31, 2023 | -7.35 Mn |
| Dec 31, 2022 | -7.85 Mn |
| Sep 30, 2022 | -7.08 Mn |
| Jun 30, 2022 | -4.78 Mn |
| Mar 31, 2022 | 985,863.00 |
| Dec 31, 2021 | -11.55 Mn |
| Sep 30, 2021 | -4.06 Mn |
| Jun 30, 2021 | -2.94 Mn |